Chugai Pharmaceutical Co., Ltd. CHGCF
OTC PK
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | 6.85B | 6.91B | |
| Total Other Revenue | -- | -- | 1.15B | 1.11B | |
| Total Revenue | -- | -- | 8.01B | 8.02B | |
| Cost of Revenue | -- | -- | 2.37B | 2.33B | |
| Gross Profit | -- | -- | 5.63B | 5.70B | |
| SG&A Expenses | -- | -- | 748.65M | 727.19M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -75.18M | -17.91M | |
| Total Operating Expenses | -- | -- | 4.27B | 4.22B | |
| Operating Income | -- | -- | 3.73B | 3.80B | |
| Income Before Tax | -- | -- | 3.72B | 3.80B | |
| Income Tax Expenses | -- | -- | 1.08B | 1.11B | |
| Earnings from Continuing Operations | -- | -- | 2.65K | 2.69K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | 2.65B | 2.69B | |
| EBIT | -- | -- | 3.73B | 3.80B | |
| EBITDA | -- | -- | 3.94B | 4.01B | |
| EPS Basic | -- | -- | 1.61 | 1.64 | |
| Normalized Basic EPS | -- | -- | 0.67 | 0.70 | |
| EPS Diluted | -- | -- | 1.61 | 1.64 | |
| Normalized Diluted EPS | -- | -- | 0.67 | 0.70 | |
| Average Basic Shares Outstanding | -- | -- | 6.58B | 6.58B | |
| Average Diluted Shares Outstanding | -- | -- | 6.58B | 6.58B | |
| Dividend Per Share | -- | -- | 0.72 | 0.64 | |
| Payout Ratio | -- | -- | 40.48% | 39.82% | |